EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische Studie

Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test

Kieren J Mather iD, Andrea Mari iD, Tim Heise, J Hans DeVries iD, Ming Hua, Shweta Urva, Tamer Coskun, Axel Haupt, Robert J Heine, Edward Pratt, Melissa K Thomas iD, Zvonko Milicevic

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae319 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Kieren J Mather und 11 weiteren Autor:innen. Beteiligte Einrichtung: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

In a clinical study, tirzepatide, a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist (GIP/GLP-1RA), provided superior glycemic control vs the GLP-1RA semaglutide. The physiologic mechanisms are incompletely understood.

Objective

This work aimed to evaluate treatment effects by model-based analyses of mixed-meal tolerance test (MMTT) data.

Methods

A 28-week double–blind, randomized, placebo-controlled trial of patients with type 2 diabetes treated with metformin was conducted at 2 clinical research centers in Germany. Interventions included tirzepatide 15 mg, semaglutide 1 mg, and placebo. Main outcome measures included glycemic control, model-derived β-cell function indices including insulin secretion rate (ISR) at 7.2–mmol/L glucose (ISR7.2), β-cell glucose sensitivity (β-CGS), insulin sensitivity, and estimated hepatic insulin-to-glucagon ratio.

Results

Tirzepatide significantly reduced fasting glucose and MMTT total glucose area under the curve (AUC) vs semaglutide (P < .01). Incremental glucose AUC did not differ significantly between treatments; therefore, greater total glucose AUC reduction with tirzepatide was mainly attributable to greater suppression of fasting glucose. A greater reduction in total ISR AUC was achieved with tirzepatide vs semaglutide (P < .01), in the context of greater improvement in insulin sensitivity with tirzepatide (P < .01). ISR7.2 was significantly increased with tirzepatide vs semaglutide (P < .05), showing improved β-CGS. MMTT-derived β-CGS was increased but not significantly different between treatments. Both treatments reduced fasting glucagon and total glucagon AUC, with glucagon AUC significantly reduced with tirzepatide vs semaglutide (P < .01). The estimated hepatic insulin-to-glucagon ratio did not change substantially with either treatment.

Conclusion

These results suggest that the greater glycemic control observed for tirzepatide manifests as improved fasting glucose and glucose excursion control, due to improvements in ISR, insulin sensitivity, and glucagon suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Secreting CellsGlucagon-Like PeptidesDiabetes Mellitus, Type 2Insulin ResistanceBlood GlucoseHypoglycemic AgentsHumansMaleMiddle AgedFemaleDouble-Blind MethodAgedGlycemic ControlInsulinMealsAdultMetforminGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Stichwörter der Autor:innen

glucagonglucose controlinsulin sensitivitymeal tolerance testtirzepatideβ-cell function

Substanzen

Glucagon-Like PeptidesBlood GlucoseHypoglycemic AgentsInsulinMetforminGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatideSemaglutide

Autor:innen und Institutionen

  • Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
  • Institute of Neuroscience, National Research Council, 2-35122 Padua, Italy.
  • Profil Institute for Metabolic Research, 41460 Neuss, Germany.

ORCID-Profile: Kieren J Mather, Andrea Mari, J Hans DeVries, Melissa K Thomas

Zitieren

APA

Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., Thomas, M. K., & Milicevic, Z. (2024). Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae319

Vancouver

Mather KJ, Mari A, Heise T, DeVries JH, Hua M, Urva S, et al. Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae319

BibTeX
@article{Mather2024,
  author = {Mather, Kieren J and Mari, Andrea and Heise, Tim and DeVries, J Hans and Hua, Ming and Urva, Shweta and Coskun, Tamer and Haupt, Axel and Heine, Robert J and Pratt, Edward and Thomas, Melissa K and Milicevic, Zvonko},
  title = {Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae319}
}
Kostenlos starten →